{"id":7868,"date":"2025-09-07T18:56:38","date_gmt":"2025-09-07T13:26:38","guid":{"rendered":"https:\/\/chiralpedia.com\/blog\/?p=7868"},"modified":"2025-10-02T23:40:12","modified_gmt":"2025-10-02T18:10:12","slug":"part-4-stereochemistry-in-drug-action-and-pharmacology","status":"publish","type":"post","link":"https:\/\/chiralpedia.com\/blog\/part-4-stereochemistry-in-drug-action-and-pharmacology\/","title":{"rendered":"Part 4: Stereochemistry in Drug Action and Pharmacology"},"content":{"rendered":"\n

\u201cWhy one enantiomer heals while the other may harm – the pharmacology of chirality<\/strong>\u201d<\/mark><\/em><\/p>\n\n\n\n

Introduction<\/strong><\/p>\n\n\n\n

Chirality doesn\u2019t just influence drug properties in theory \u2013 it has very real consequences in pharmacology. In this section, we explore how stereochemistry affects drug action<\/strong> at multiple levels: pharmacodynamics (drug-receptor interactions) and pharmacokinetics (absorption, distribution, metabolism, excretion). We will define terms like eutomer <\/a>(the more active enantiomer) and distomer<\/a> (the less active one) and introduce the concept of the eudismic ratio<\/a> (the ratio of activities of enantiomers). Through famous case studies \u2013 thalidomide<\/em>, ibuprofen<\/em>, omeprazole<\/em>, and others \u2013 we will see examples of enantioselectivity in therapeutic and toxic effects. This part underlines why, for many drugs, it is not sufficient to develop a racemate without understanding each enantiomer\u2019s behavior.<\/p>\n\n\n\n

Pharmacodynamics \u2013<\/strong> Chirality in Drug-Receptor Interactions<\/strong><\/p>\n\n\n\n

Most biological targets (receptors, enzymes, ion channels, DNA) are chiral environments. Imagine a receptor as a glove: it can distinguish between a left hand and a right hand. Thus, enantiomers of a chiral drug often have different affinities or intrinsic activities at the target site. One enantiomer may bind snugly to the receptor\u2019s binding pocket (like the correct hand in a glove) \u2013 this is typically the eutomer<\/strong>, responsible for the desired pharmacological effect. The mirror-image drug may fit poorly or differently – distomer<\/strong>; it could be inactive, or sometimes it binds to a different site or receptor altogether, potentially causing off-target effects. [Read more @ <https:\/\/chiralpedia.com\/blog\/chiral-pharmacology-the-mirror-image-of-drug-development\/<\/a>>.<\/p>\n\n\n\n

Case Study 1: Propranolol<\/strong><\/p>\n\n\n\n

For example, propranolol<\/strong>, a non-selective \u03b2-blocker: the l-(\u2013)-propranolol<\/strong> enantiomer (also known as S-propranolol) is a potent \u03b2-adrenergic antagonist, while d-(+)-propranolol<\/strong> (R-propranolol) is ~100-fold less active at \u03b2-receptors. This is because the binding pocket of the \u03b2-receptor \u201csees\u201d the two enantiomers as different shapes. In clinical use, propranolol was introduced as a racemate, but essentially all the \u03b2-blocking activity comes from the l-enantiomer. The other enantiomer is considered mostly inert in terms of the primary action (though it might contribute to side effects or have different pharmacokinetics).<\/p>\n\n\n\n

Case Study 1: Thalidomide<\/strong><\/p>\n\n\n\n

Another striking example: Thalidomide<\/strong>. This is a textbook case where chirality literally spelled the difference between a drug and a poison. However, a complicating factor is that thalidomide racemizes in vivo (interconverts between enantiomers), so even administering a single enantiomer wouldn\u2019t have completely averted tragedy \u2013 an important cautionary note we\u2019ll revisit in Part 6.<\/strong> Nonetheless, this case alerted the world to the importance of evaluating each enantiomer of chiral drugs separately. [For an in-depth look, explore the full blog \ud83d\udc49 <https:\/\/chiralpedia.com\/blog\/thalidomide-tragedy-the-story-and-lessons\/<\/a>>.<\/p>\n\n\n\n

\"\"
The two enantiomers of thalidomide were found to have distinct properties: one (often reported as the R-enantiomer) had sedative and anti-nausea effects (the intended therapeutic action for morning sickness in pregnant women), while the other (S-enantiomer) was teratogenic, causing severe birth defects.<\/em><\/figcaption><\/figure>\n\n\n\n

Case Study 3: Ibuprofen<\/strong><\/p>\n\n\n\n

A classic case in analgesics is ibuprofen<\/strong>. Ibuprofen has a chiral center in the propionic acid side chain. The marketed product for decades was racemic ibuprofen. It was known that the S-(+)-ibuprofen<\/strong> is the active form that inhibits cyclooxygenase (COX) and thus inflammation\/pain. The R-(\u2013)-ibuprofen is much less effective at COX (eudismic ratio for COX inhibition is significant). Interestingly, humans (and many animals) have an enzyme (an isomerase in the liver) that slowly converts R-ibuprofen to S-ibuprofen. In vivo studies showed that about 60% of R-ibuprofen could be converted to the active S-form in some populations, though in others (like certain ethnic groups) the conversion was far less (only ~25% in Chinese populations). This partially mitigates the disadvantage of selling ibuprofen as a racemate \u2013 some of the \u201cless active\u201d enantiomer is turned into the active one in the body. Nevertheless, recognizing the advantage of a single-enantiomer product, a pure S-(+)-ibuprofen (called dexibuprofen<\/strong>) was later developed and marketed in some countries, offering potentially faster onset or efficacy at lower doses, though clinical differences are modest. This highlights how metabolism and pharmacodynamics together must be considered: the seemingly inactive enantiomer of ibuprofen isn\u2019t completely wasteful because it can activate via chiral inversion<\/a> in vivo, but that depends on individual metabolism.<\/p>\n\n\n\n

Case Study 4: Warfarin<\/strong><\/strong><\/p>\n\n\n\n

Warfarin,<\/strong> an anticoagulant. Warfarin\u2019s enantiomers are both active as anticoagulants (they inhibit vitamin K epoxide reductase, VKOR, which is involved in clotting factor maturation). However, S-warfarin<\/strong> is about 3\u20135 times more potent than R-warfarin in terms of anticoagulant effect. They are metabolized by different cytochrome P450 enzymes: S-warfarin is primarily metabolized by CYP2C9, whereas R-warfarin by CYP3A4 and others. As a result, drug interactions or genetic polymorphisms in CYP2C9 affect S-warfarin\u2019s clearance more \u2013 making the pharmacokinetics of the racemate a composite of two different half-lives. Clinically, warfarin is still used as the racemate (Coumadin), but dosing and monitoring (INR checks) account for the net effect. This case shows that even when both enantiomers share the same qualitative<\/em> activity (both anticoagulant), one might be considered the main contributor while the other is weaker and hangs around longer. Indeed, this can cause complications: differences in enantiomer metabolism mean that the enantiomeric composition in plasma can shift over time or with interactions.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Eudismic Ratio and Enantioselectivity<\/strong><\/p>\n\n\n\n

The eudismic ratio<\/a> (ER<\/strong>) is a concept that quantifies how big the activity difference is between two enantiomers. It can be defined, for instance, as the ratio of EC50 or IC50 of the distomer to the eutomer (so a larger number indicates a bigger difference). A high eudismic ratio means one enantiomer is much more potent than the other. For example, if the (S)-enantiomer of a hypothetical drug has an EC50 of 1 nM at a receptor, and the (R)-enantiomer\u2019s EC50 is 100 nM, the eudismic ratio is 100. Such information guides drug development decisions: if one enantiomer is overwhelmingly more active, there is a strong argument to develop only that enantiomer as the drug (to minimize dosing and side effects from the inert or harmful partner). If both enantiomers have similar activity (ratio near 1), a racemate might suffice.<\/p>\n\n\n\n

\"\"\/
Select \u03b2-blockers<\/strong> with their eudismic ratio or index values<\/mark>
Reflecting the degree of stereoselectivity<\/figcaption><\/figure>\n\n\n\n

Enantioselective Pharmacokinetics<\/strong><\/p>\n\n\n\n

Beyond receptor binding, chirality can influence all ADME aspects:
– Absorption:<\/strong> Sometimes one enantiomer is absorbed faster or to a greater extent. For example, L-amphetamine is absorbed more readily than D-amphetamine from the gut. The reasons can be complex (differential transporter affinity or first-pass metabolism differences).
– Distribution:<\/strong> Plasma protein binding or tissue distribution can differ. One enantiomer might fit better into plasma albumin\u2019s binding site, altering free drug levels.
– Metabolism:<\/strong> As seen with warfarin, different enantiomers often have different metabolic routes and rates because enzymes (being chiral proteins) may preferentially recognize one over the other. Another example: omeprazole<\/strong> (mentioned earlier). Omeprazole is a proton pump inhibitor marketed originally as a racemate (Prilosec). Its S-enantiomer, esomeprazole<\/strong>, was later marketed. What was the advantage? It turns out S-omeprazole is metabolized more slowly than R-omeprazole in humans \u2013 specifically, the S-enantiomer has lower clearance and less inter-individual variability. This leads to higher and more consistent plasma levels of the active drug, for a given dose, when using pure S compared to the racemate. In practical terms, 20 mg of esomeprazole (S-only) can achieve acid suppression comparable to 40 mg of racemic omeprazole, and with less variability between patients. The reason is enantioselective metabolism: R-omeprazole undergoes faster first-pass metabolism via CYP2C19, whereas S-omeprazole is metabolized a bit slower and more by CYP3A4; plus some individuals are poor metabolizers for R due to CYP2C19 genetics. By using the single S-enantiomer (and doubling the dose relative to one enantiomer\u2019s contribution in racemate), AstraZeneca could both extend the patent life (a so-called \u201cracemic switch\u201d strategy and claim a pharmacokinetic benefit. This illustrates how one enantiomer can be preferred not necessarily because the other is inactive, but because the other is less predictable or efficient in the body.
– Excretion:<\/strong> If a drug\u2019s excretion involves chiral interactions (like active transport in kidneys), enantiomers might be excreted at different rates.<\/p>\n\n\n\n

\"\"
ADME Aspects Influenced by Chirality<\/mark><\/figcaption><\/figure>\n\n\n\n

Case Studies<\/strong><\/p>\n\n\n\n